Modified antibody compositions, methods of making and using thereof
First Claim
1. An activatable antibody that in an activated state binds Epidermal Growth Factor Receptor (EGFR),the activatable antibody comprising:
- an antibody or an antigen binding fragment thereof (AB) that specifically binds to EGFR;
a masking moiety (MM) that inhibits the binding of the AB in an uncleaved state to EGFR and wherein the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NO;
1, 218-220, 236-265 and 266; and
at least one cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease selected from the group consisting of urokinase-type plasminogen activator (uPA), legumain, and matriptase (MT-SP1) and the substrate for uPA comprises the amino acid sequence LSGRSDNH (SEQ ID NO;
271).
2 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
185 Citations
137 Claims
-
1. An activatable antibody that in an activated state binds Epidermal Growth Factor Receptor (EGFR),the activatable antibody comprising:
-
an antibody or an antigen binding fragment thereof (AB) that specifically binds to EGFR; a masking moiety (MM) that inhibits the binding of the AB in an uncleaved state to EGFR and wherein the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NO;
1, 218-220, 236-265 and 266; andat least one cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease selected from the group consisting of urokinase-type plasminogen activator (uPA), legumain, and matriptase (MT-SP1) and the substrate for uPA comprises the amino acid sequence LSGRSDNH (SEQ ID NO;
271). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
-
-
51. An activatable antibody that in an activated state binds Epidermal Growth Factor Receptor (EGFR), the activatable antibody comprising:
-
an antibody or an antigen binding fragment thereof (AB) that specifically binds to EGFR; a masking moiety (MM) that inhibits the binding of the AB in an uncleaved state to EGFR, wherein the MM comprises the amino acid sequence CISPRGCPDGPYVM (SEQ ID NO;
218) or CISPRGCPDGPYVMY (SEQ ID NO;
238); andat least one cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease. - View Dependent Claims (52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)
-
-
100. An activatable antibody that in an activated state binds Epidermal Growth Factor Receptor (EGFR),the activatable antibody comprising:
-
an antibody or an antigen binding fragment thereof (AB) that specifically binds to EGFR; a masking moiety (MM) that inhibits the binding of the AB in an uncleaved state to EGFR, wherein the MM comprises the amino acid sequence CISPRGCPDGPYVM (SEQ ID NO;
218);at least one cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease selected from the group consisting of urokinase-type plasminogen activator (uPA), legumain and matriptase (MT-SP
1) and wherein the substrate for uPA comprises the amino acid sequence LSGRSDNH (SEQ ID NO;
271);a first linking peptide (LP1) comprising the amino acid sequence GGSGGS (SEQ ID NO;
111); anda second linking peptide (LP2) comprising the amino acid sequence GS, wherein the activatable antibody in the uncleaved state has the structural arrangement from N-terminus to C-terminus as follows;
MM-LP1-CM-LP2-AB or AB-LP2-CM-LP 1-MM.- View Dependent Claims (101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137)
-
Specification